RxDoctor Payments Data

James Fox, MD

Cardiovascular Disease · Traverse City, MINPI 1740275379

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Edwards Lifesciences at 29.1% of the total. Reporting peaked in 2022 at $235 and has fallen 69.4% since, to $72 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.

$417in general payments, 2019–2025

Across 9 payments — averaging $46.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$121
  • Abbott$118
  • Penumbra, Inc.$114
  • Abiomed$23
  • Cardiovascular Systems Inc.$21
  • W. L. Gore & Associates, Inc.$20
$2,000in research payments, 2019–2025

Across 2 payments — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$2K

What the payments were for

  • Food & beverage$417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$417 in reported general payments places this provider in the 20th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan →

Medicare billing

Part B allowed, 2024
$124,403
Medicare patients
1,295
Services billed
2,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban398$490,827
XareltoRivaroxaban77$90,098
EntrestoSacubitril/Valsartan17$15,394
Repatha SureclickEvolocumab18$15,290
JardianceEmpagliflozin15$7,829
Metoprolol Succinate348$6,946
Ranolazine ErRanolazine26$2,693
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$2,603
Atorvastatin Calcium160$2,184
Rosuvastatin Calcium101$2,064
Bumetanide44$1,882
Verapamil ErVerapamil Hcl30$1,694
Carvedilol142$1,650
Losartan Potassium118$1,441
Potassium Chloride32$1,019

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Traverse City

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →